TScan: A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients with Autoimmune Disease

Grants and Contracts Details

StatusActive
Effective start/end date12/15/22 → 1/8/26

Funding

  • TScan Therapeutics: $122,609.00